WCG has announced the acquisition of VeraSci, a global provider of specialty scientific and eClinical software to support the design and execution of clinical trials focused on central nervous system disorders.
VeraSci provides clients with solutions that aim to improve data quality in clinical trials, including endpoint and assessment services, rater training and certification, language and translation support, and eCOA and ePRO technologies. With its Pathway technology platform, VeraSci enables the collection of data that can be used to assess symptoms, cognition, and functional capacity in a wide range of therapeutic indications.
Moving forward, VeraSci will be known as WCG VeraSci. The organization will retain its leadership structure and continue to operate from its headquarters in North Carolina.
